Efgartigimod Alfa in Myasthenia Gravis: NCT06587867 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 28 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 3
Clinical phase
Unknown status
Recruitment status
30
Planned enrollment
2025-05-01
Primary-completion proxy
Executive view
NCT06587867 evaluates Efgartigimod Alfa in Myasthenia Gravis. The disclosed sponsor is University Health Network, the design is Interventional, and the geographic footprint is Canada. The first listed primary endpoint is Total Myasthenia Gravis Impairment Index (MGII) score, assessed over through study completion for 42 weeks.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT06587867 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Myasthenia Gravis landscape. Drug & Asset MCP drug_fetch was queried for Efgartigimod Alfa, while Company & Deal Intelligence MCP organization_fetch was queried for University Health Network.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT06587867 | Efgartigimod Alfa | Phase 3 / Unknown status | University Health Network | Canada | Total Myasthenia Gravis Impairment Index (MGII) score through study completion for 42 weeks | 2025-05-01 |
| NCT06558279 | Efgartigimod/Hyaluronidase | Phase 3 / Active, not recruiting | argenx SE | Cyprus, Czechia, United States, Japan, United Kingdom, United Arab Emirates, Portugal, Spain, Greece, Canada, Sweden, South Korea, Netherlands, Austria, Belgium, China, Finland, Poland, Denmark, Italy, Serbia, France, Australia, Germany | MGII (PRO) ocular score change from baseline to day 29 in part A Up to 29 days | 2026-01-12 |
| NCT06548620 | RD-06-04 | Early Phase 1 / Withdrawn | Nanjing Bioheng Biotech Co., Ltd. | China | Incidence of treatment-emergent adverse events, serious adverse events and incidence of adverse events of special inte… up to 2 years | 2026-08-31 |
| NCT06540144 | Rozanolixizumab | Phase 3 / Enrolling by invitation | UCB Biopharma SRL | Japan, Turkey, Taiwan Province, Poland, Italy | Occurrence of serious Treatment-Emergent Adverse Events (TEAEs) up to the End of Study (EOS) Visit From Baseline up to the EOS Visit (up to 52 weeks) | 2027-08-17 |
| NCT06517758 | Iptacopan Hydrochloride | Phase 3 / Active, not recruiting | Novartis Pharmaceuticals Canada, Inc. | Argentina, United States, Japan, United Kingdom, Portugal, Spain, Greece, South Korea, China, Poland, Denmark, Brazil, Italy, Israel, Serbia, France, Australia, Germany | Change from baseline to Month 6 in Myasthenia Gravis Activity of Daily Living (MG-ADL) total score Baseline to Month 6 | 2027-04-30 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT06587867 is a Phase 3, unknown status study with 30 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.
The primary endpoint is “Total Myasthenia Gravis Impairment Index (MGII) score” over “through study completion for 42 weeks.” The retrieved endpoint description is: Myasthenia Gravis Impairment Index (MGII) is a composite score based on a patient self-reported multidomain questionnaire as well as physician-documented clinical measures. MGII has 22 patient-reported and 6 physician-assessed items with a final composite score of 84, with higher score signifying greater disability..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 30 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Myasthenia Gravis. These records do not establish direct evidence for NCT06587867 unless the registration number matches.
Management of Exacerbations and Rescue Therapy in the Phase 3 Myasthenia Gravis Inebilizumab Trial
Phase 3; n=238; exacerbation(26-week): HR = 0.41(95.0% CI, 0.24 - 0.7); exacerbation(26-week): HR = 0.41(95.0% CI, 0.24 - 0.7) Source: https://pubmed.ncbi.nlm.nih.gov/42573995/
A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod IV in Adult Participants With Acetylcholi…
Phase 3; n=119; MG-ADL Total Score Change From Baseline(Least Squares Mean) = -1.90 points on a scale (90% Confidence Interval, -2.51 to -1.28); MG-ADL Total Score Change From Baseline(Least Squares Mean) = -3.35 points on a scale (90% Confidence Interval, -3.98 to -2.72) Source: https://clinicaltrials.gov/ct2/show/results/NCT06298552
Assessment of sustained health- related quality of life in Phase 3 Vivacity-MG3 Trial of Nipocalimab versus Placebo in Generalized Myasthenia Gravis
Phase 3; n=129; EQ-5D-VAS(24-week) = 37.1 % ; EQ-5D-VAS(24-week) = 55.2 % Source: https://onlinelibrary-wiley-com.sutd.idm.oclc.org/journal/14681331
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Efgartigimod Alfa is indexed as Fc Fragment with FcRn biology and a global stage of Approved. The asset profile lists argenx SE as an originator or developer.
University Health Network is indexed in Canada with the website http://www.uhn.ca. Operates as a research and teaching hospital network that provide health care and medical services The record lists 19 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Efgartigimod Alfa is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT06587867
Protocol source: https://clinicaltrials.gov/study/NCT06587867
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 28 September 2026.
Efgartigimod Alfa in Myasthenia Gravis is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Total Myasthenia Gravis Impairment Index (MGII) score and 2025-05-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
